文献速递胸部儿科影像MR

使用129Xe MRI纵向监测囊性纤维化肺病年幼儿童对Lumacaftor/Ivacaftor的治疗反应

Longitudinal Monitoring of Lumacaftor/Ivacaftor Response in Young Children with Cystic Fibrosis Lung Disease Using 129Xe MRI.
PubMed 文献 · Acad Radiol · 2025-07-10

18例囊性纤维化患者中,9例启动lumacaftor/ivacaftor治疗(8.7±2.4岁),9例为对照(15.3±4.3岁),在基线、短期(6±3月)和长期(15±4月)随访时行肺功能、LCI2.5和129Xe MRI。治疗组VDP和DDI保持稳定,变化显著低于对照组(ΔVDP12 P=0.018,ΔDDI12 P=0.007),但第2至第3次随访VDP显著增加(P=0.025),肺功能和LCI无显著变化。

要点

  • 129Xe MRI的VDP和DDI可检测调节剂治疗期间囊性纤维化儿童肺功能变化。
  • 治疗组短期VDP和DDI稳定,变化显著低于对照组(P=0.018和P=0.007)。
  • 治疗组第2至第3次随访VDP显著增加(P=0.025),而肺功能和LCI无显著变化。

核心结论

  • 129Xe MRI在检测接受与未接受调节剂治疗的儿童囊性纤维化患者功能变化方面具有高敏感性;短期调节剂治疗期间129Xe通气指标保持稳定,此后2年内出现下降,提示129Xe MRI可能作为监测肺功能和疾病进展的临床工具有价值,即使在小样本患者中。

研究设计与样本

  • 纵向研究,共18例囊性纤维化患者,其中9例(8.7±2.4岁,3男/6女)启动lumacaftor/ivacaftor治疗(第1次随访后48±51天),9例(15.3±4.3岁,5男/4女)为对照;在基线、短期(6±3月)和长期(15±4月)随访时采集肺功能、多次呼吸洗脱(肺清除指数LCI2.5)和129Xe MRI;使用非参数检验比较组间肺功能、LCI、VDP和DDI变化。

关键影像表现/征象

  • 对照组年龄显著更大(P=0.0028),初始VDP有更高趋势(14.7±8.1% vs 6.9±6.0%),DDI有更高趋势(14.4±24.7 vs 4.7±4.3)。
  • 基线肺功能和LCI在两组间无差异。
  • 治疗组治疗后VDP和DDI保持稳定(ΔVDP12=-0.56±2.1%,ΔDDI12=1.1±4.0),变化显著低于对照组(ΔVDP12=2.75±2.82%,P=0.018;DDI12=8.88±7.42,P=0.007)。
  • 从第2次至第3次随访,治疗组VDP显著增加(ΔVDP23=3.33±2.79%,P=0.025),对照组为ΔVDP23=-1.7±4.8%。
  • 肺功能或LCI未见显著变化。

局限性

  • 对照组年龄显著更大(P=0.0028),初始VDP和DDI有更高趋势。
  • 结论指出即使在小样本患者中129Xe MRI也可能有价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Hyperpolarized 129Xe magnetic resonance imaging (MRI) can sensitively detect subtle abnormalities in subjects with pulmonary disease. In this work, we assess lung disease progression and treatment response to Lumacaftor/Ivacaftor in patients with cystic fibrosis.

METHODS: 18 cystic fibrosis (CF) patients underwent a longitudinal study: nine subjects (8.7±2.4years, 3M/6F) initiated lumacaftor/ivacaftor therapy (48±51days post-Visit 1), and 9 (15.3±4.3years, 5M/4F) served as controls. Spirometry, multiple breath washout (Lung Clearance Index, LCI2.5), and 129Xe MRI were acquired at baseline, short-term (6±3months), and long-term (15±4months) follow-ups. Changes in spirometry measurements, LCI, ventilation defect percentage (VDP), and defect distribution index (DDI) assessed by 129Xe MRI, were compared between groups using non-parametric tests.

RESULTS: The control group was significantly older (P=0.0028) and trended toward higher initial VDP (14.7±8.1% vs 6.9±6.0%) and DDI (14.4±24.7 vs 4.7±4.3). Baseline spirometry and LCI showed no differences between groups. In the treatment group, VDP and DDI remained stable after treatment (ΔVDP12= -0.56±2.1%, ΔDDI12= 1.1±4.0) but the change was significantly lower than in controls (ΔVDP12= 2.75±2.82%, P=0.018; DDI12= 8.88±7.42, P=0.007). From Visit-2 to Visit-3, VDP increased significantly in the treatment group (ΔVDP23 = 3.33±2.79%, P=0.025) versus controls (ΔVDP23= -1.7±4.8%). No significant changes occurred in spirometry or LCI.

CONCLUSION: 129Xe MRI demonstrated high sensitivity in detecting functional changes between pediatric CF patients on and off modulator therapy. In the short term, 129Xe ventilation measures remained stable with modulator therapy and demonstrated declines in the 2 years following. These findings highlight 129Xe MRI's potential as a valuable clinical tool for monitoring lung function and disease progression, even with small cohorts of patients.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Bdaiwi AS, Roach DJ, West ME, et al. Longitudinal Monitoring of Lumacaftor/Ivacaftor Response in Young Children with Cystic Fibrosis Lung Disease Using 129Xe MRI. Acad Radiol. 2025. PMID: 40645890. doi:10.1016/j.acra.2025.06.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。